Skip to main content
Clinical Trials/NCT00915499
NCT00915499
Completed
N/A

Is Adaptive Servo-Ventilation Therapeutically More Effective Than Continuous Positive Airway Pressure In Treating Complex Sleep Apnea Syndrome?

ResMed6 sites in 1 country66 target enrollmentMay 2009

Overview

Phase
N/A
Intervention
Not specified
Conditions
Complex Sleep Apnea Syndrome
Sponsor
ResMed
Enrollment
66
Locations
6
Primary Endpoint
Apnea-hypopnea Index (AHI) Per Polysomnography (PSG) at the End of Treatment Period
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

The purpose of this study is to determine whether adaptive servo-ventilation (ASV) or continuous positive airway pressure (CPAP) is better at treating complex sleep apnea over time.

Detailed Description

Between 3 and 19% of patients with clinical and polysomnographic features of obstructive sleep apnea syndrome (OSA) develop a high-frequency of central apneas and/or disruptive Cheyne-Stokes respiratory syndrome after application of continuous positive airway pressure (CPAP), a pattern called the complex sleep apnea syndrome (CompSAS). The trial seeks to determine the efficacy of the ASV vs. CPAP modes for the treatment of CompSAS over time. Baseline clinical and laboratory data will be collected, patients will be randomized to one of the two treatments. Overall study participation is approximately 3 months.

Registry
clinicaltrials.gov
Start Date
May 2009
End Date
December 2011
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
ResMed
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of complex sleep apnea syndrome (CompSAS)
  • Naive to PAP therapy
  • Requires CPAP ≤15 cm H2O

Exclusion Criteria

  • Requires supplemental oxygen or with a baseline SaO2 \<90%
  • Requires CPAP \> 15 cm H2O
  • Primary diagnosis of moderate to severe chronic obstructive pulmonary disease, neuromuscular disease, chronic hyperventilation, stroke, cognitive impairment, such that could impair ability to answer subjective questions (study questionnaires) or unstable heart failure
  • Any contraindication for nasal or oro-nasal positive airway pressure, such as claustrophobia, severe nasal obstruction, or impaired mental status

Outcomes

Primary Outcomes

Apnea-hypopnea Index (AHI) Per Polysomnography (PSG) at the End of Treatment Period

Time Frame: 3 months

AHI refers to the number of apneas and hypopneas that occurred per hour of sleep

Secondary Outcomes

  • Quality of Life Measured by the Sleep Apnea Quality of Life Index (SAQLI)(3 months)

Study Sites (6)

Loading locations...

Similar Trials